NCT03067896

Brief Summary

Regional anesthesia has become more popular in cesarean deliveries because most of the parturients prefer being awake during the birth process. In addition, regional anesthesia may be a safer method than general. In spinal anesthesia local anesthetics alone may not be enough for an effective postoperative analgesia and hemodynamic stability of the patient wich is crucial during cesarean section. So far many adjuvants have been used to augment the analgesia produced by intrathecal local anesthetics and to reduce their adverse effects . Various intrathecal adjuvants to local anaesthetics have found to improve the quality and extend duration of spinal block. Prolongation of duration of spinal block is desirable both for long procedures and for postoperative pain relief. Efficacy and safty of intrathecal magnesium as analgesic adjuvant has been tested by several clinical trails in recent years.Antinociceptive effect of magnesium appears to be relevant for the management of chronic and post operative pain. These effects are primarily based on regulation of calcium influx in to the cell. Magnesium blocks calcium influx and non competitively antagonizes NMDA channels. NMDA receptor signelling plays an impartent in determining the duration of acute pain3).) addition of magnesium to spinal anaesthesia improved postoperative analgesia in orthopedic setting. addition of intrathecal magnesium sulfate to 10 mg bupivacaine plus 25µg fentanyl prolonged spinal anaesthesia in patients undergoing lower extremity surgery. Dexmedetomidine is a highly selective 2-adrenergic agonist which has been used as pre-medication and as an adjuvant to general anesthesia.Dexmedetomidine have several beneficial actions during perioperative period. They decrease sympathetic tone with attenuation of the neuroendocrine and haemodynamic response to anaesthesia and surgery, reduce anaesthetic and opiod requirement, cause sedation and analgesia. Dexmedetomidine was first introduced into clinical practice as a short term intravenous sedative in intensive care. Like any other adjuvant dexmedetomidine is not free from adverse effects. Use of dexmedetomidine is often associated with a decrease in heart rate and blood pressure.Dexmedetomidine was used to enhance the analgesic property of local anaesthetics like lidocaine bupivacaine and ropivacaine. In vivo and in vitro studies indicated that these local anaesthetics had significant neurotoxicity. Dexmedetomidine showed protective or growth promoting properties in tissues, including nerve cells from cortex. Intrathecal dexmedetomidine has a neuroprotective effect similar to methylprednisolone. The mechanism by which intrathecal alpha 2-adrenergic agonists prolong the motor and sensory block of local anesthetics is not clear. It may be an additive or synergistic effect secondary to the different mechanisms of action of local anesthetic and alpha 2 adrenergic agonist. The local anesthetics act by blocking sodium channels, whereas the alpha 2 adrenergic agonist acts by binding to pre synapyic C fibre and post synaptic dorsal horn neurons. Intrathecal alpha 2 adrenergic agonist produce analgesia by depressing the realease of C fibre transmission by hyperpolarization of post synaptic dorsal horn neurons. Li et al observed that Glutamate is involved in excitatory neurotransmission nociception and plays an essential role in relaying noxious stimuli in the spinal cord. Intrathecal injection of alpha 2 adrenergic agonists produces potent antinociceptive effects by altering spinal neurotransmitter release and effectively treats acute pain.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
78

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Jun 2015

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2015

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

July 12, 2015

Completed
1.6 years until next milestone

First Posted

Study publicly available on registry

March 1, 2017

Completed
Same day until next milestone

Primary Completion

Last participant's last visit for primary outcome

March 1, 2017

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

March 1, 2017

Completed
Last Updated

March 1, 2017

Status Verified

February 1, 2017

Enrollment Period

1.8 years

First QC Date

July 12, 2015

Last Update Submit

February 25, 2017

Conditions

Keywords

spinal blockstress responsedexmedetomidineintrathecally

Outcome Measures

Primary Outcomes (1)

  • Visual Analogue Scale

    analgesia will be given if VAS is 4 or more

    6 hours

Secondary Outcomes (2)

  • heart rate

    6 hours

  • blood pressure

    6 hours

Other Outcomes (2)

  • APGAR Score

    5 minutes

  • plasma concentration of stress hormones

    3 hours

Study Arms (3)

Group C

ACTIVE COMPARATOR

Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml

Drug: Bupivacaine

Group D

ACTIVE COMPARATOR

Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline .

Drug: Dexmedetomidine

Group M

ACTIVE COMPARATOR

Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with magnesium sulfate 50 mg in 0.5 ml normal saline .

Drug: Magnesium Sulfate

Interventions

Patients will receive intrathecal hyperbaric bupivacaine 12.5 mg in 2.5 ml

Group C

Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml with dexmdetomidine 5 µg in 0.5 ml normal saline

Group D

Patients will receive intrathecal hyperbaric bupivacaine 10 mg in 2 ml magnesium sulfate 50 mg in 0.5 ml normal saline

Group M

Eligibility Criteria

Age18 Years - 45 Years
Sexfemale
Healthy VolunteersYes
Age GroupsAdult (18-64)

You may qualify if:

  • Age 18 to 45 years
  • Undergo elective cesarean section under spinal anesthesia.
  • ASA physical status Ӏ-ӀӀ .
  • Singleton pregnancy .
  • At least 36 weaks gestation .

You may not qualify if:

  • Women with a history of cardiac , liver , or kidney diseases .
  • Women with allergy to amide local anesthetics or medications included in the study .
  • Women with any neurological problem .
  • Any contraindication of regional anesthesia .
  • Women with evidence of intrauterine growth restriction or fetal compromise .
  • Failed or insatisfactory spinal block .

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ahmed Talaat Ahmed

Asyut, 71111, Egypt

RECRUITING

Related Publications (1)

  • Mostafa MF, Herdan R, Fathy GM, Hassan ZEAZ, Galal H, Talaat A, Ibrahim AK. Intrathecal dexmedetomidine versus magnesium sulphate for postoperative analgesia and stress response after caesarean delivery; randomized controlled double-blind study. Eur J Pain. 2020 Jan;24(1):182-191. doi: 10.1002/ejp.1476. Epub 2019 Sep 12.

MeSH Terms

Conditions

Fractures, Stress

Interventions

BupivacaineDexmedetomidineMagnesium Sulfate

Condition Hierarchy (Ancestors)

Fractures, BoneWounds and Injuries

Intervention Hierarchy (Ancestors)

AnilidesAmidesOrganic ChemicalsAniline CompoundsAminesImidazolesAzolesHeterocyclic Compounds, 1-RingHeterocyclic CompoundsMagnesium CompoundsInorganic ChemicalsSulfatesSulfuric AcidsSulfur AcidsSulfur Compounds

Study Officials

  • Zain E. Hassan, MD

    Assiut University

    STUDY DIRECTOR

Central Study Contacts

MOHAMED F. MOSTAFA, MD

CONTACT

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Assisstant lecturer of anesthesia and intensive care

Study Record Dates

First Submitted

July 12, 2015

First Posted

March 1, 2017

Study Start

June 1, 2015

Primary Completion

March 1, 2017

Study Completion

March 1, 2017

Last Updated

March 1, 2017

Record last verified: 2017-02

Locations